• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

梅奥诊所60年(1940 - 1999年)间治疗的甲状腺乳头状癌:2444例连续治疗患者的初始治疗时间趋势及长期预后

Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients.

作者信息

Hay Ian D, Thompson Geoffrey B, Grant Clive S, Bergstralh Eric J, Dvorak Catherine E, Gorman Colum A, Maurer Megan S, McIver Bryan, Mullan Brian P, Oberg Ann L, Powell Claudia C, van Heerden Jon A, Goellner John R

机构信息

Department of Internal Medicine, Division of Endocrinology, Mayo Clinic, 200 First Street SW, Rochester, Minnesota 55905, USA.

出版信息

World J Surg. 2002 Aug;26(8):879-85. doi: 10.1007/s00268-002-6612-1. Epub 2002 May 21.

DOI:10.1007/s00268-002-6612-1
PMID:12016468
Abstract

It is uncertain whether more extensive primary surgery and increasing use of radioiodine remnant ablation (RRA) for papillary thyroid carcinoma (PTC) have resulted in improved rates of cause-specific mortality (CSM) and tumor recurrence (TR). Details of the initial presentation, therapy, and outcome of 2444 PTC patients consecutively treated during 1940-1999 were recorded in a computerized database. Patients were followed for more than 43,000 patient-years. The 25-year rates for CSM and TR were 5% and 14%, respectively. Temporal trends were analyzed for six decades. During the six decades, the proportion with initial MACIS (distant Metastasis, patient Age, Completeness of resection, local Invasion, and tumor Size) scores <6 were 77%, 82%, 84%, 86%, 85%, and 82%, respectively (p = 0.06). Lobectomy accounted for 70% of initial procedures during 1940-1949 and 22% during 1950-1959; during 1960-1999 bilateral lobar resection (BLR) accounted for 91% of surgeries (p <0.001). RRA after BLR was performed during 1950-1969 in 3% but increased to 18%, 57%, and 46% in successive decades (p <0.001). The 40-year rates for CSM and TR during 1940-1949 were significantly higher (p = 0.002) than during 1950-1999. During the last 50 years the 10-year CSM and TR rates for the 2286 cases did not significantly change with successive decades. Moreover, the 10-year rates for CSM and TR were not significantly improved during the last five decades of the study, either for the 1917 MACIS <6 patients or the 369 MACIS < 6 patients. Increasing use of RRA has not apparently improved the already excellent outcome, achieved before 1970, in low risk (MACIS <6) PTC patients managed by near-total thyroidectomy and conservative nodal excision.

摘要

对于甲状腺乳头状癌(PTC)而言,更广泛的初次手术以及增加放射性碘残留消融(RRA)的使用是否已使特定病因死亡率(CSM)和肿瘤复发率(TR)得到改善尚不确定。1940年至1999年期间连续治疗的2444例PTC患者的初始表现、治疗及结局细节被记录在一个计算机化数据库中。对患者进行了超过43000患者年的随访。CSM和TR的25年发生率分别为5%和14%。对六个十年的时间趋势进行了分析。在这六个十年中,初始MACIS(远处转移、患者年龄、切除完整性、局部侵犯和肿瘤大小)评分<6的比例分别为77%、82%、84%、86%、85%和82%(p = 0.06)。在1940 - 1949年期间,叶切除术占初始手术的70%,在1950 - 1959年期间占22%;在1960 - 1999年期间,双侧叶切除术(BLR)占手术的91%(p <0.001)。在1950 - 1969年期间,BLR后进行RRA的比例为3%,但在随后的几十年中分别增至18%、57%和46%(p <0.001)。1940 - 1949年期间CSM和TR的40年发生率显著高于1950 - 1999年期间(p = 0.002)。在过去50年中,2286例患者的10年CSM和TR发生率并未随连续几十年而显著变化。此外,在研究的最后五十年中,对于1917例MACIS <6的患者或369例MACIS <6的患者,CSM和TR的10年发生率也没有显著改善。增加RRA的使用显然并未改善1970年之前通过近全甲状腺切除术和保守性淋巴结切除术治疗的低风险(MACIS <6)PTC患者已取得的优异结局。

相似文献

1
Papillary thyroid carcinoma managed at the Mayo Clinic during six decades (1940-1999): temporal trends in initial therapy and long-term outcome in 2444 consecutively treated patients.梅奥诊所60年(1940 - 1999年)间治疗的甲状腺乳头状癌:2444例连续治疗患者的初始治疗时间趋势及长期预后
World J Surg. 2002 Aug;26(8):879-85. doi: 10.1007/s00268-002-6612-1. Epub 2002 May 21.
2
Papillary Thyroid Carcinoma (PTC) in Children and Adults: Comparison of Initial Presentation and Long-Term Postoperative Outcome in 4432 Patients Consecutively Treated at the Mayo Clinic During Eight Decades (1936-2015).儿童和成人甲状腺乳头状癌(PTC):梅奥诊所80年间(1936 - 2015年)连续治疗的4432例患者的初始表现与术后长期结果比较
World J Surg. 2018 Feb;42(2):329-342. doi: 10.1007/s00268-017-4279-x.
3
Papillary thyroid microcarcinoma: a study of 900 cases observed in a 60-year period.甲状腺微小乳头状癌:一项为期60年的900例病例研究。
Surgery. 2008 Dec;144(6):980-7; discussion 987-8. doi: 10.1016/j.surg.2008.08.035.
4
Managing patients with papillary thyroid carcinoma: insights gained from the Mayo Clinic's experience of treating 2,512 consecutive patients during 1940 through 2000.甲状腺乳头状癌患者的管理:从梅奥诊所1940年至2000年连续治疗2512例患者的经验中获得的见解。
Trans Am Clin Climatol Assoc. 2002;113:241-60.
5
Local and regional control in patients with papillary thyroid carcinoma: specific indications of external radiotherapy and radioactive iodine according to T and N categories in AJCC 6th edition.甲状腺乳头状癌患者的局部和区域控制:根据美国癌症联合委员会(AJCC)第6版的T和N分类,外照射放疗和放射性碘的具体指征
Endocr Relat Cancer. 2006 Dec;13(4):1159-72. doi: 10.1677/erc.1.01320.
6
Management and outcome of recurrent well-differentiated thyroid carcinoma.复发性高分化甲状腺癌的管理与预后
Arch Otolaryngol Head Neck Surg. 2004 Jul;130(7):819-24. doi: 10.1001/archotol.130.7.819.
7
High recurrent rate of multicentric papillary thyroid carcinoma.多中心性乳头状甲状腺癌的高复发率。
Ann Surg Oncol. 2009 Sep;16(9):2609-16. doi: 10.1245/s10434-009-0565-7. Epub 2009 Jun 16.
8
Contralateral papillary thyroid cancer at completion thyroidectomy has no impact on recurrence or survival after radioiodine treatment.全甲状腺切除术后对侧甲状腺乳头状癌对放射性碘治疗后的复发或生存无影响。
Surgery. 2006 Dec;140(6):1043-7; discussion 1047-9. doi: 10.1016/j.surg.2006.08.007. Epub 2006 Nov 1.
9
Selective use of radioactive iodine in the postoperative management of patients with papillary and follicular thyroid carcinoma.放射性碘在乳头状和滤泡状甲状腺癌患者术后管理中的选择性应用。
J Surg Oncol. 2006 Dec 15;94(8):692-700. doi: 10.1002/jso.20696.
10
Papillary thyroid carcinoma: factors influencing recurrence and survival.甲状腺乳头状癌:影响复发和生存的因素
Ann Surg Oncol. 2008 May;15(5):1518-22. doi: 10.1245/s10434-008-9859-4. Epub 2008 Mar 7.

引用本文的文献

1
Evolving Paradigm in Radioactive Iodine Therapy for Differentiated Thyroid Cancer: Historical Perspectives, Current Practices and Future Directions.分化型甲状腺癌放射性碘治疗的发展范式:历史回顾、当前实践与未来方向
Diagnostics (Basel). 2025 Jun 5;15(11):1438. doi: 10.3390/diagnostics15111438.
2
Internal Jugular Vein Reconstruction with Cephalic Vein Interposition Graft: A Case Report and Review of Literature.采用头静脉间置移植术重建颈内静脉:1例病例报告及文献复习
Indian J Surg Oncol. 2025 Feb;16(1):198-202. doi: 10.1007/s13193-024-02063-0. Epub 2024 Aug 13.
3
Nomogram Predicting Progression-Free Survival in Locally Advanced Papillary Thyroid Cancer with Recurrent Laryngeal Nerve Invasion.
预测局部晚期伴喉返神经侵犯的乳头状甲状腺癌无进展生存期的列线图
J Otolaryngol Head Neck Surg. 2025 Jan-Dec;54:19160216251314750. doi: 10.1177/19160216251314750.
4
Analysis of prognostic factors and establishment of a recurrence risk prediction model for papillary thyroid carcinoma based on BRAF stratification.基于BRAF分层的甲状腺乳头状癌预后因素分析及复发风险预测模型的建立
Endocrine. 2025 May;88(2):511-522. doi: 10.1007/s12020-025-04177-z. Epub 2025 Feb 3.
5
Lobectomy sufficiency for 1-4 cm differential thyroid cancer: a large retrospective study in China.1-4厘米分化型甲状腺癌的肺叶切除术充足性:中国一项大型回顾性研究
Sci Rep. 2024 Dec 30;14(1):32113. doi: 10.1038/s41598-024-83893-4.
6
The Prognostic Impact of Tumor Size and BRAF Mutational Status in Middle Eastern Differentiated Thyroid Cancer.肿瘤大小和BRAF突变状态对中东地区分化型甲状腺癌的预后影响
J Clin Endocrinol Metab. 2025 May 19;110(6):1617-1623. doi: 10.1210/clinem/dgae740.
7
Neoadjuvant Treatment in Locally Advanced Thyroid Carcinoma.局部晚期甲状腺癌的新辅助治疗
J Clin Med. 2024 Sep 27;13(19):5769. doi: 10.3390/jcm13195769.
8
European Society of Endocrine Surgeons (ESES) consensus statement on advanced thyroid cancer: definitions and management.欧洲内分泌外科学会(ESES)关于晚期甲状腺癌的共识声明:定义与管理
Br J Surg. 2024 Aug 2;111(8). doi: 10.1093/bjs/znae199.
9
Effect and Safety of Apatinib as Neoadjuvant Therapy in Locally Advanced Differentiated Thyroid Cancer: A Phase 2 Trial.阿帕替尼作为局部晚期分化型甲状腺癌新辅助治疗的疗效与安全性:一项2期试验
J Endocr Soc. 2024 Jul 12;8(9):bvae132. doi: 10.1210/jendso/bvae132. eCollection 2024 Jul 26.
10
Exploration of the prognostic value of methylation regulators related to m5C in papillary thyroid carcinoma.探索与 m5C 相关的甲基化调节剂在甲状腺乳头状癌中的预后价值。
Medicine (Baltimore). 2024 Jun 21;103(25):e38623. doi: 10.1097/MD.0000000000038623.